Long-Term Implications of Antibiotic Use on Gut Health and Microbiota in Populations Including Patients With Cystic Fibrosis

Deane, Jennifer; Rea, Mary C.; Fouhy, Fiona; Stanton, Catherine; Ross, R. Paul; Plant, Barry J.

doi:10.1016/b978-0-12-802304-4.00011-6

Cited by 4 publications

(5 citation statements)

References 224 publications

(277 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…What is meaningful, we observed down-regulation of genes involved in β-oxidation of the fatty acids, which may result in changes of the membranes structure, fluidity and consequently cell shape. This statement can be supported by an observed higher minimum inhibitory concentration for colistin 56,57 that acts as a surface active agent (see Fig. 3C).…”

Section: Discussionmentioning

confidence: 58%

Phenotypic plasticity of Escherichia coli upon exposure to physical stress induced by ZnO nanorods

Matuła

Richter

Janczuk-Richter

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Evolution of bacteria to selective chemical pressure (e.g. antibiotics) is well studied in contrast to the influence of physical stressors. Here we show that instantaneous physical stress in a homogeneous environment (without concentration gradient) induces fast adaptation of Escherichia coli . We exposed E . coli to a large number of collisions of around 10 5 per bacterium per second with sharp ZnO nanorods. The pressure exerted on the bacterial cell wall was up to 10 GPa and induced phenotype changes. The bacteria’s shape became more spherical, the density of their periplasm increased by around 15% and the average thickness of the cell wall by 30%. Such E . coli cells appeared almost as Gram-positive bacteria in the standard Gram staining. Additionally, we observed a combination of changes occurring at the genomic level (mutations identified in form of single nucleotide polymorphisms) and down-regulation of expression of 61 genes encoding proteins involved in β-oxidation of fatty acids, glycolysis, the citric acid cycle, as well as uptake of amino acids and enzyme cofactors. Thus, we show that bacteria undergo phenotypic changes upon instantaneous, acute physical stress without any obviously available time for gradual adaptation.

show abstract

Section: Discussionmentioning

confidence: 58%

Phenotypic plasticity of Escherichia coli upon exposure to physical stress induced by ZnO nanorods

Matuła

Richter

Janczuk-Richter

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Therefore, ESBL producing bacteria respond poorly to β-lactams, leading to higher medical costs, prolonged hospital stays, loss of prophylactic protection, and increased mortality [3,4]. ESBLs are not effective in hydrolyzing cephamycins (e.g., cefoxitin and cefotetan) and carbapenems (e.g., imipenem and meropenem), therefore, these antibiotic agents-notably carbapenems, are recommended for the treatment of infections due to ESBL producers [5,6]. ESBL enzymes are mediated by genes, commonly bla CTX-M , bla TEM, and bla SHV , which are harbored by self-transmissible conjugative plasmids that are horizontally shared within the same and different species of bacteria [7,8].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Existence of Multiple ESBL Genes among Phenotypically Confirmed ESBL Producing Klebsiella pneumoniae and Escherichia coli Concurrently Isolated from Clinical, Colonization and Contamination Samples from Neonatal Units at Bugando Medical Center, Mwanza, Tanzania

et al. 2021

View full text Add to dashboard Cite

The proportions and similarities of extended-spectrum β-lactamase (ESBL) producing K. pneumoniae (ESBL-KP) and E. coli (ESBL-EC) carrying multiple ESBL genes is poorly known at our setting. This study investigated the existence of multiple ESBL genes (blaCTX-M, blaTEM, and blaSHV) among ESBL-KP and ESBL-EC concurrently isolated from clinical, colonization, and contamination samples from neonatology units in Mwanza-Tanzania. Twenty and 55 presumptive ESBL-EC and ESBL-KP, respectively, from a previous study archived at −80 °C were successfully recovered for this study. Isolates were screened and confirmed for production of ESBLs by phenotypic methods followed by multiplex PCR assay to determine ESBL genes. All (100%) and 97.3% of presumptive ESBL isolates were phenotypically confirmed by Clinical and Laboratory Standards Institute (CLSI) and modified double-disc synergy methods, respectively. About 93.3% (70/75) of phenotypically confirmed ESBL isolates had at least one ESBL gene, whereby for 62.9% (44/70), all ESBL genes (blaCTX-M, blaTEM, and blaSHV) were detected. Eight pairs of ESBL bacteria show similar patterns of antibiotics susceptibility and ESBL genes. ESBL-KP and ESBL-EC, concurrently isolated from clinical, colonization and contamination samples, harbored multiple ESBL genes. Further, eight pairs of ESBL isolates had similar patterns of antibiotics susceptibility and ESBL genes, suggesting transmission of and/or sharing of mobile genetic elements (MGEs) among ESBL-KP and ESBL-EC.

show abstract

“…Lincosamides are mainly used to treat anaerobic infections caused by gram-positive organisms, including infections developed by methicillin resistant Staphylococcus aureus [90]. Originally this class of antibiotics comes from natural product lincomycin, but derivatives also include clindamycin and pirlimycin, from which clindamycin is the most clinically relevant lincosamide [90,91]. Drugs such as lincomycin and clindamycin are bacteriostatic and inhibit protein synthesis.…”

Section: Lincosamidesmentioning

confidence: 99%

From Blood to Regenerative Tissue: How Autologous Platelet-Rich Fibrin Can Be Combined with Other Materials to Ensure Controlled Drug and Growth Factor Release

Egle

Šalma

Dubņika

2021

IJMS

View full text Add to dashboard Cite

The purpose of this review is to examine the latest literature on the use of autologous platelet-rich fibrin as a drug and growth factor carrier system in maxillofacial surgery. Autologous platelet-rich fibrin (PRF) is a unique system that combines properties such as biocompatibility and biodegradability, in addition to containing growth factors and peptides that provide tissue regeneration. This opens up new horizons for the use of all beneficial ingredients in the blood sample for biomedical purposes. By itself, PRF has an unstable effect on osteogenesis: therefore, advanced approaches, including the combination of PRF with materials or drugs, are of great interest in clinics. The main advantage of drug delivery systems is that by controlling drug release, high drug concentrations locally and fewer side effects within other tissue can be achieved. This is especially important in tissues with limited blood supply, such as bone tissue compared to soft tissue. The ability of PRF to degrade naturally is considered an advantage for its use as a “warehouse” of controlled drug release systems. We are focusing on this concentrate, as it is easy to use in manipulations and can be delivered directly to the surgical site. The target audience for this review are researchers and medical doctors who are involved in the development and research of PRFs further studies. Likewise, surgeons who use PRF in their work to treat patients and who advice patients to take the medicine orally.

show abstract

Long-Term Implications of Antibiotic Use on Gut Health and Microbiota in Populations Including Patients With Cystic Fibrosis

Cited by 4 publications

References 224 publications

Phenotypic plasticity of Escherichia coli upon exposure to physical stress induced by ZnO nanorods

Phenotypic plasticity of Escherichia coli upon exposure to physical stress induced by ZnO nanorods

Existence of Multiple ESBL Genes among Phenotypically Confirmed ESBL Producing Klebsiella pneumoniae and Escherichia coli Concurrently Isolated from Clinical, Colonization and Contamination Samples from Neonatal Units at Bugando Medical Center, Mwanza, Tanzania

From Blood to Regenerative Tissue: How Autologous Platelet-Rich Fibrin Can Be Combined with Other Materials to Ensure Controlled Drug and Growth Factor Release

Contact Info

Product

Resources

About